의약품 접근성 향상을 위한 방안 고찰
Review of Programs for Improving Patient’s Access to Medicines
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: This study presented the analysis period, the complexity of combined therapy and comparator choice as the key limitations in the economic evaluation of new drugs, and discussed programs for coping with these limitations. Methods: This study evaluated the post-evaluation, risk-sharing agreement, extra funding program, and flexible incremental cost-effectiveness ratio (ICER) threshold as actions or programs that would increase accessibility to costly new drugs. The study also presented the cases of other countries. The application of the post-evaluation was considered to deal with high uncertainty regarding new drugs. Results: The risk-sharing agreement was introduced in European countries as well as South Korea and has been responsible for the shift from using the financial schemes to outcome-based schemes. The drug funding program has had troubled in securing stable extra funds. The application of higher ICER in the economic evaluation of expensive and innovative oncology drugs was criticized because of the inequity between oncology patients and patients with other diseases. Conclusion: Therefore, introducing and applying actions that would increase the accessibility to costly new drugs in South Korea have been deemed necessary after careful reviews and discussions with various stakeholders (insurer, policy makers, pharmaceutical companies and patients).
Abstract
Objective: This study presented the analysis period, the complexity of combined therapy and comparator choice as the key limitations in the economic evaluation of new drugs, and discussed programs for coping with these limitations. Methods: This study evaluated the post-evaluation, risk-sharing agreement, extra funding program, and flexible incremental cost-effectiveness ratio (ICER) threshold as actions or programs that would increase accessibility to costly new drugs. The study also presented the cases of other countries. The application of the post-evaluation was considered to deal with high uncertainty regarding new drugs. Results: The risk-sharing agreement was introduced in European countries as well as South Korea and has been responsible for the shift from using the financial schemes to outcome-based schemes. The drug funding program has had troubled in securing stable extra funds. The application of higher ICER in the economic evaluation of expensive and innovative oncology drugs was criticized because of the inequity between oncology patients and patients with other diseases. Conclusion: Therefore, introducing and applying actions that would increase the accessibility to costly new drugs in South Korea have been deemed necessary after careful reviews and discussions with various stakeholders (insurer, policy makers, pharmaceutical companies and patients).
참고문헌 (31)
- "OECD Health Data 2015" (2015)[URL]
- "2015 Statistical Yearbook of Health and Welfare" (2015)[URL]
- Drummond MF, "Methods for the economic evaluation of health care programmes", pp.12~13 (2015), Oxford University Press
- Ha DM, "Analysis of the current performance of new drugs reimbursement and perception on policy after introducing positive list system in Korea", pp.2010
- "ISPOR Global Health Care System Road Map"[URL]
- 허대석, "암 치료에 있어서 맞춤의학의 현황과 전망", 대한의사협회지, 58(11), pp.1021~1026 (2015), 대한의사협회[DOI]
- Cho BC, "Paradigm change of lung cancer chemotherapy" (2016), Yonsei Cancer Center Press conference
- "Economic evaluation on pharmaceuticals guideline" (2011)[URL]
- Davis S, "How do we evaluate technologies which are not cost-effective at a zero price?", ISPOR 18th Annual European Congress
- Strengthening the publicity of pharmaceuticals production and supply. National Health Insurance Service Research Report, "Kwon HY", ~ (2013)
- 양봉민, "World Health Organization의 비용효과 권고역치에 대한 비판적 탐색", 보건의료기술평가, 3(2), pp.69~74 (2015), 한국보건의료기술평가학회[DOI]
- Raffery J, "Multiple sclerosis risk sharing scheme: a costly failure", BMJ, (340), pp.c1672~ (2010)
- 김윤, "4대 중증질환 보장성 강화정책의 평가", 대한의사협회지, 57(3), pp.198~203 (2014), 대한의사협회[DOI]
- 박실비아, "신약의 가격지불에서 위험분담계약의 동향과 고찰", 보건경제와 정책연구, 16(2), pp.125~153 (2010), 한국보건경제정책학회
- 이영실, "주요 외국의 의약품 위험분담제도에 대한 고찰: 계약현황과 사후관리방안을 중심으로", 보건의료기술평가, 5(1), pp.13~21 (2017), 한국보건의료기술평가학회[DOI]
- Carlson JJ, "A taxonomy and examination of performance-based reimbursement scheme between healthcare payers and manufacturers", Health Policy, 96(3), pp.179~190 (2010)[DOI]
- 손현순, "위험분담제도에 대한 고찰: 항암제 사례를 중심으로", 한국임상약학회지, 23(2), pp.89~96 (2013), 한국임상약학회
- "Ministry of Health and Welfare Annual Report 2015" (2016)[URL]
- van de Voore K, "Market-access agreements for anti-cancer drugs", JRSM open, 108(5), pp.166~170 (2015)[DOI]
- "List of technologies with approved Patient Access Schemes"[URL]
- "UK National Institute for Health and Care Excellence (NICE) Homepage"[URL]
- "Cancer Drug Fund (CDF) Homepage"[URL]
- Mihajlovic J, "Reimbursement of targeted cancer therapies within three different European health care systems", ISPOR 17th European Annual Congress
- "Negotiation list"[URL]
- "New drug funding program (NDFP) Homepage"[URL]
- "Pharmaceutical benefits advisory committee (PBAC) outcomes"[URL]
- Graduate School of Pharmaceutical Management Chung-Ang University, "An innovative approach for evaluating the value of new medicines", International conference
- "Future directions for pharmaceutical policy in the new era of high cost medicines"[URL]
- "Establish roadmap for systematic management of health insurance drug costs"[URL]
- "Improvement of accessibility of 4 major severity diseases - focusing on funding for rare diseases and anticancer drugs-"[URL]
- "Problems of reimbursement drug pricing system & improvement Plan. Korea Institute for Health and Social Affairs Issue & Focus;No 222"[URL]